Law, Politics, and Expert Panels at the US Food and Drug Administration

The FDA’s recent shift from formal advisory committees to ad hoc “expert panels” risks undermining the agency’s scientific independence by soliciting advice that appears aligned with predetermined policy positions. The authors argue this approach raises legal concerns under the Federal Advisory Committee Act and reflects a troubling prioritization of political signaling over evidence-based decisionmaking.